Biotech / Deals
AbbVie Acquires Capstan Therapeutics for $2.1 Billion to Advance In Vivo CAR-T Therapies
AbbVie is expanding its presence in the cell and gene therapy space with the acquisition of Capstan Therapeutics. This deal, valued at $2.1 billion, will give AbbVie access to Capstan's novel in vivo CAR-T technology, which holds promise fo...